case_images: PMC9576937_01
case_images: PMC9576937_02
case_images: (A) Red arrows show lung metastases at baseline and (B) after 12 weeks of therapy with ribociclib.
case_images: BCTT-14-351-g0001.jpg
case_images: PMC9576937_02_BCTT-14-351-g0001.jpg
case_images: f0001
case_images: Baseline laboratory parameters: cancer antigen (CA) 15-3 was 285.1 U/mL (0.0-30.0 U/mL) (Figure S1), carcinoembryonic antigen (CEA) of 24.1 ng/mL (0.0-5.0 ng/mL) (Figure S2), WBC count of 8.10 K/microL, hemoglobin of 14.9 g/dL, platelet count of 249 K/microL, and complete metabolic panel was normal. The CT scan showed partial pulmonary (lung metastasis to right upper lobe 13 x 11 vs 16 x 12 mm) and hepatic response (metastasis to eighth hepatic segment 15 x 13 vs 19 mm) (Figure 1A and B, Figure 2A and B) and stable bone and brain disease.
case_images: (A) Red arrows show liver metastases at baseline and (B) after 12 weeks of therapy with ribociclib.
case_images: BCTT-14-351-g0002.jpg
case_images: PMC9576937_02_BCTT-14-351-g0002.jpg
case_images: f0002
case_images: Baseline laboratory parameters: cancer antigen (CA) 15-3 was 285.1 U/mL (0.0-30.0 U/mL) (Figure S1), carcinoembryonic antigen (CEA) of 24.1 ng/mL (0.0-5.0 ng/mL) (Figure S2), WBC count of 8.10 K/microL, hemoglobin of 14.9 g/dL, platelet count of 249 K/microL, and complete metabolic panel was normal. The CT scan showed partial pulmonary (lung metastasis to right upper lobe 13 x 11 vs 16 x 12 mm) and hepatic response (metastasis to eighth hepatic segment 15 x 13 vs 19 mm) (Figure 1A and B, Figure 2A and B) and stable bone and brain disease.
case_images: (A) Red arrows show lung metastases at baseline and (B) after 10 cycles of therapy with ribociclib.
case_images: BCTT-14-351-g0003.jpg
case_images: PMC9576937_10_BCTT-14-351-g0003.jpg
case_images: f0003
case_images: The biopsy revealed infiltrating carcinoma, ER (95%), PR (90%), Ki-67 (60%), HER2 (1-positive not overexpressed/negative) (Figure S3).
case_images: (A) Red arrows show liver metastases at baseline and (B) after 10 cycles of therapy with ribociclib.
case_images: BCTT-14-351-g0004.jpg
case_images: PMC9576937_02_BCTT-14-351-g0004.jpg
case_images: f0004
case_images: By August 2018, after 10 cycles of therapy, the revaluation CT scan showed further reduction of lung (lung metastasis to the right upper lobe 11 x 6 vs 16 x 12 mm) and liver metastases (metastasis to the eighth hepatic segment 12 x 9 vs 19 mm and to the fifth hepatic segment 13 vs 15 mm) (Figure 3A and B, Figure 4A and B).
case_images: (A) Red arrows show brain metastases at baseline and (B) after 10 cycles of therapy with ribociclib.
case_images: BCTT-14-351-g0005.jpg
case_images: PMC9576937_02_BCTT-14-351-g0005.jpg
case_images: f0005
case_images: The same CT scan showed an increase in size of the right occipital metastasis (22 vs 5 mm) (Figure 5A and B).
case_images: PMC9576937_03
case_images: (A) Hepatic complete response and (B) stable brain disease after 31 months of therapy with ribociclib.
case_images: BCTT-14-351-g0006.jpg
case_images: PMC9576937_03_BCTT-14-351-g0006.jpg
case_images: f0006
case_images: In July 2020 after 31 months of therapy, CT scan showed complete hepatic response and stable disease in other sites (Figure 6A and B).
case_images: (A) and (B) Red arrows show liver metastases after 49 months of therapy with ribociclib.
case_images: BCTT-14-351-g0007.jpg
case_images: PMC9576937_03_BCTT-14-351-g0007.jpg
case_images: f0007
case_images: In February 2021, after 3 years and 2 months of therapy, CT scan showed hepatic progression of disease (Figure 7A and B).
case_images: PMC9576937_04
case_images: PMC9576937_05
case_images: PMC9576937_06
case_images: First CT scan evaluation. (A) Red arrows in the figures show sternum lytic metastasis, (B) lung metastasis of 30 mm diameter, (C) mediastinal lymph node of 30 mm diameter and right breast tumor, and (D) axillary lymph node.
case_images: BCTT-14-351-g0008.jpg
case_images: PMC9576937_06_BCTT-14-351-g0008.jpg
case_images: f0008
case_images: A highly suspicious metastatic lesion was observed in some right axillary and mediastinal lymphadenopathies, lung, and bone (sternum and right hemisome of D8) (Figure 8A-D).
case_images: PMC9576937_07
case_images: CT scan evaluation after treatment. (A) Red arrows in the figures show sternum lytic metastasis, (B) mediastinal lymph node, (C) axillary lymph node, and (D) lung metastasis.
case_images: BCTT-14-351-g0009.jpg
case_images: PMC9576937_07_BCTT-14-351-g0009.jpg
case_images: f0009
case_images: As per the CT scan evaluation (April 2020), partial response in breast was observed, lymph nodes were maintained, skeletal disease was stable, and the pulmonary nodule was hardly recognizable (Figure 9A-D).
case_images: PET FDG evaluation.
case_images: BCTT-14-351-g0010.jpg
case_images: PMC9576937_07_BCTT-14-351-g0010.jpg
case_images: f0010
case_images: Disease re-evaluations with positron emission tomography fluorodeoxyglucose (PET FDG) evaluations (August 2020 and January 2021) showed a low hypermetabolism in the breast localization (SUV max 3.2) and no pathological uptake in the lung, lymph node, and skeletal sites (Figure 10).
case_images: PMC9576937_08
case_images: CT scan with bone windows. (A) Humerus shows a lytic lesion into the posterior humeral head, the cortical part of the humerus head is conserved, (B) area of osteosclerosis into the previous lytic lesion, as response to treatment, (C) further osteosclerosis area in relation to the partial recalcification of the lesion.
case_images: BCTT-14-351-g0011.jpg
case_images: PMC9576937_09_BCTT-14-351-g0011.jpg
case_images: f0011
case_images: After 11 months of treatment, CT scan showed disappearance of the known lymph nodes, stability of adrenal gland lesions, and an important response of the left humerus lytic metastasis (Figure 11B). After 25 months, the humerus lesion showed healing (Figure 11C) and stabilization of the other lesions.
case_images: PMC9576937_09
case_images: CT scan with bone windows. (A) Humerus shows a lytic lesion into the posterior humeral head, the cortical part of the humerus head is conserved, (B) area of osteosclerosis into the previous lytic lesion, as response to treatment, (C) further osteosclerosis area in relation to the partial recalcification of the lesion.
case_images: BCTT-14-351-g0011.jpg
case_images: PMC9576937_09_BCTT-14-351-g0011.jpg
case_images: f0011
case_images: After 11 months of treatment, CT scan showed disappearance of the known lymph nodes, stability of adrenal gland lesions, and an important response of the left humerus lytic metastasis (Figure 11B). After 25 months, the humerus lesion showed healing (Figure 11C) and stabilization of the other lesions.
case_images: PMC9576937_10
case_images: (A) Red arrows show lung metastases at baseline and (B) after 10 cycles of therapy with ribociclib.
case_images: BCTT-14-351-g0003.jpg
case_images: PMC9576937_10_BCTT-14-351-g0003.jpg
case_images: f0003
case_images: The biopsy revealed infiltrating carcinoma, ER (95%), PR (90%), Ki-67 (60%), HER2 (1-positive not overexpressed/negative) (Figure S3).
case_images: (A-D and G-J) CT scan of bone, lymph node, lung; (E and F) follow-up CT scan lung and lymph node.
case_images: BCTT-14-351-g0012.jpg
case_images: PMC9576937_12_BCTT-14-351-g0012.jpg
case_images: f0012
case_images: Follow-up CT scan in October 2017 showed reduction of all pulmonary and lymph nodal metastases (Figure 12E and F). CT scan showed stable disease until the last examination in October 2021 (Figure 12G-J).
case_images: PMC9576937_11
case_images: PMC9576937_12
case_images: (A-D and G-J) CT scan of bone, lymph node, lung; (E and F) follow-up CT scan lung and lymph node.
case_images: BCTT-14-351-g0012.jpg
case_images: PMC9576937_12_BCTT-14-351-g0012.jpg
case_images: f0012
case_images: Follow-up CT scan in October 2017 showed reduction of all pulmonary and lymph nodal metastases (Figure 12E and F). CT scan showed stable disease until the last examination in October 2021 (Figure 12G-J).